New Releases from NCBI BookshelfCipaglucosidase Alfa (Pombiliti) With Miglustat (Opfolda): Indication: Cipaglucosidase alfa is indicated in combination with the enzyme stabilizer Opfolda (65 mg miglustat capsule) for the treatment of adult patients with late-onset Pompe disease (acid α-glucosidase [GAA] deficiency) weighing ≥ 40 kg. Miglustat is an enzyme stabilizer indicated in combination with Pombiliti (cipaglucosidase alfa) for the treatment of adult patients with late-onset Pompe disease (acid α-glucosidase [GAA] deficiency) weighing ≥ 40 kg. Cipaglucosidase alfa must be used in combination with 65 mg miglustat capsules: Reimbursement Recommendation [Internet].​Cipaglucosidase Alfa (Pombiliti) With Miglustat (Opfolda): Indication: Cipaglucosidase alfa is indicated in combination with the enzyme stabilizer Opfolda (65 mg miglustat capsule) for the treatment of adult patients with late-onset Pompe disease (acid α-glucosidase [GAA] deficiency) weighing ≥ 40 kg. Miglustat is an enzyme stabilizer indicated in combination with Pombiliti (cipaglucosidase alfa) for the treatment of adult patients with late-onset Pompe disease (acid α-glucosidase [GAA] deficiency) weighing ≥ 40 kg. Cipaglucosidase alfa must be used in combination with 65 mg miglustat capsules: Reimbursement Recommendation [Internet].